{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-24-000012","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2024-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.771488+00:00","generated_at":"2026-06-06T07:04:41.613433+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Recursion Pharma CBO Virani transitions to Senior Strategic Advisor; Kinn joins exec team","bullets":["Dr. Shafique Virani stepped down as Chief Business Officer effective Feb 6, 2024, to become Senior Strategic Advisor.","Matthew Kinn, previously SVP Business Development, assumes all CBO responsibilities on Recursion's executive team.","Virani receives advisory fees of $1,000/hour (min $25k/month Feb–Jul, then $15k/month) and continued equity vesting.","If terminated before Aug 1, 2024, Virani gets a lump sum starting at $390k (Feb) decreasing $65k/month."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-24-000012","json":"https://secwatch.observer/filing/0001601830-24-000012.json","markdown":"https://secwatch.observer/filing/0001601830-24-000012.md","text":"https://secwatch.observer/filing/0001601830-24-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000012/0001601830-24-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000012/rxrx-20240206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T07:04:41.613433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8839ceda1a","claim":"Shafique Virani changed role as Senior Strategic Advisor at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"Dr. Shafique Virani, the Chief Business Officer of Recursion Pharmaceuticals, Inc. (the “Company” or “Recursion”) transitioned into a new role as a Senior Strategic Advisor.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000012/0001601830-24-000012-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Senior Strategic Advisor"}],"fact_type":"executive_change"},{"claim_id":"d80ac92977","claim":"Matthew Kinn was appointed as Chief Business Officer at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"Matthew Kinn, Senior Vice President, Business Development and Corporate Initiatives joined Recursion’s executive team and assumed all responsibilities previously held by Dr. Virani.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000012/0001601830-24-000012-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"joined"},{"label":"Role","value":"Chief Business Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}